Metagenomi says the oversubscribed $175 million Series B financing it completed Tuesday will enable it to advance its lead in vivo and ex vivo gene editing therapy programs into the clinic.
Moderna and Metagenomi Establish Collaboration to Develop Next-Generation In Vivo Gene Editing Therapeutics - read this article along with other careers information, tips and advice on BioSpace